Payment overview · 2025
General Payments
$656.61
42 reported records · 17 companies
Healthcare provider profile · identity verified
Blake Cover, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · OMAHA, NE · NPI 1225484934
Verified facts
What the public records show
CMS Open Payments records show Blake Cover, M.D. received $656.61 in general payments during 2025 across 42 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 22.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ingrezza, Mounjaro, Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $146.95 | 22.4% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $79.27 | 12.1% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $62.99 | 9.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $59.80 | 9.1% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $47.25 | 7.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.93 | 5.5% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.44 | 5.2% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $30.00 | 4.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.93 | 3.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $23.15 | 3.5% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.97 | 3.4% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $20.64 | 3.1% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $17.87 | 2.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.53 | 2.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.90 | 2.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.18 | 2.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $5.81 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $656.61 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $79.27 | 5 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $77.01 | 6 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $69.94 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $59.80 | 4 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $47.66 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $47.25 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.93 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $34.44 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $30.48 | 2 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $24.93 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $23.15 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $20.64 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $5.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 193 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
116 | 14 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
193 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
163 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 674 | 110 |
| Losartan Potassium | Losartan Potassium | 595 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 529 | 102 |
| Potassium Chloride | Potassium Chloride | 496 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 387 | 52 |
| Omeprazole | Omeprazole | 319 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 317 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 308 | 55 |
| Trazodone Hcl | Trazodone Hcl | 285 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 275 | 47 |
| Lisinopril | Lisinopril | 271 | 47 |
| Furosemide | Furosemide | 248 | 32 |
| Gabapentin | Gabapentin | 246 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 236 | 44 |
| Metformin Hcl Er | Metformin Hcl | 198 | 37 |
| Eliquis | Apixaban | 193 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 181 | 33 |
| Atenolol | Atenolol | 167 | 28 |
| Jardiance | Empagliflozin | 163 | 16 |
| Montelukast Sodium | Montelukast Sodium | 161 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 155 | 22 |
| Carvedilol | Carvedilol | 151 | 21 |
| Tramadol Hcl | Tramadol Hcl | 148 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 135 | 21 |
| Torsemide | Torsemide | 130 | 19 |
| Allopurinol | Allopurinol | 127 | 24 |
| Meloxicam | Meloxicam | 121 | 23 |
| Metformin Hcl | Metformin Hcl | 120 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 18 |
| Farxiga | Dapagliflozin Propanediol | 116 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 45 |
| Bupropion Xl | Bupropion Hcl | 107 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 36 |
| Warfarin Sodium | Warfarin Sodium | 104 | 16 |
| Alprazolam | Alprazolam | 102 | 25 |
| Pregabalin | Pregabalin | 98 | 19 |
| Buspirone Hcl | Buspirone Hcl | 97 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 94 | 83 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 85 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 13 |
| Januvia | Sitagliptin Phosphate | 78 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 75 | suppressed |
| Spironolactone | Spironolactone | 74 | 12 |
| Xarelto | Rivaroxaban | 74 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 73 | 11 |
| Sertraline Hcl | Sertraline Hcl | 71 | 15 |
| Ozempic | Semaglutide | 70 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 70 | 11 |
| Alendronate Sodium | Alendronate Sodium | 68 | suppressed |
| Baclofen | Baclofen | 68 | 14 |
| Famotidine | Famotidine | 67 | 13 |
| Cefdinir | Cefdinir | 64 | 44 |
| Colchicine | Colchicine | 62 | 17 |
| Trulicity | Dulaglutide | 60 | suppressed |
| Clonazepam | Clonazepam | 58 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 58 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 55 | 25 |
| Prednisone | Prednisone | 55 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 23 |
| Mounjaro | Tirzepatide | 51 | suppressed |
| Simvastatin | Simvastatin | 51 | 13 |
| Aripiprazole | Aripiprazole | 50 | suppressed |
| Olanzapine | Olanzapine | 46 | suppressed |
| Ezetimibe | Ezetimibe | 45 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 13 |
| Midodrine Hcl | Midodrine Hcl | 40 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 30 |
| Fenofibrate | Fenofibrate,micronized | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 12 |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 27 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 27 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 13 |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 19 |
| Acetazolamide | Acetazolamide | 24 | suppressed |
| Carbamazepine Er | Carbamazepine | 24 | suppressed |
| Erythromycin | Erythromycin Base | 24 | 11 |
| Lorazepam | Lorazepam | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 21 |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 12 |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Lumigan | Bimatoprost | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 14 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 13 | 13 |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $656.61 · 42 records | Teva Pharmaceuticals USA, Inc. | AIRSUPRA, ARISTADA, AUSTEDO XR, CAMZYOS, COBENFY, Dexcom G6 Transmitter, ELIQUIS, EVENITY, INGREZZA, LYBALVI, MOUNJARO, Ozempic, PROCLAIM, PROLIA, Qelbree, REXULTI, Rybelsus, UZEDY, VOQUEZNA, VRAYLAR, YUPELRI, ZENPEP | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error